BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 16818498)

  • 21. Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.
    Menendez D; Anand JR; Murphy CC; Bell WJ; Fu J; Slepushkina N; Buehler E; Martin SE; Lal-Nag M; Nitiss JL; Resnick MA
    Oncotarget; 2022; 13():332-346. PubMed ID: 35178190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A DNA repair player, ring finger protein 43, relieves etoposide-induced topoisomerase II poisoning.
    Lerksuthirat T; Wikiniyadhanee R; Stitchantrakul W; Chitphuk S; Stansook N; Pipatpanyanugoon N; Jirawatnotai S; Dejsuphong D
    Genes Cells; 2020 Nov; 25(11):718-729. PubMed ID: 32939879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
    Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.
    Caldecott K; Banks G; Jeggo P
    Cancer Res; 1990 Sep; 50(18):5778-83. PubMed ID: 2168280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo.
    Gómez-Herreros F; Romero-Granados R; Zeng Z; Alvarez-Quilón A; Quintero C; Ju L; Umans L; Vermeire L; Huylebroeck D; Caldecott KW; Cortés-Ledesma F
    PLoS Genet; 2013; 9(3):e1003226. PubMed ID: 23505375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
    Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
    Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
    DeVore RF; Corbett AH; Osheroff N
    Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements.
    Kantidze OL; Razin SV
    Gene; 2007 Apr; 391(1-2):76-9. PubMed ID: 17234368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
    Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
    Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
    Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
    Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SUMO-Targeted DNA Translocase Rrp2 Protects the Genome from Top2-Induced DNA Damage.
    Wei Y; Diao LX; Lu S; Wang HT; Suo F; Dong MQ; Du LL
    Mol Cell; 2017 Jun; 66(5):581-596.e6. PubMed ID: 28552615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
    Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
    DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
    Leontiou C; Lakey JH; Austin CA
    Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using yeast to study resistance to topoisomerase II-targeting drugs.
    Nitiss JL
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S6-13. PubMed ID: 8070029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
    Swan RL; Cowell IG; Austin CA
    Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of DNA double-strand break repair by the Ku heterodimer in mrx mutants of Saccharomyces cerevisiae.
    Wasko BM; Holland CL; Resnick MA; Lewis LK
    DNA Repair (Amst); 2009 Feb; 8(2):162-9. PubMed ID: 18992851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
    Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
    J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different mating-type-regulated genes affect the DNA repair defects of Saccharomyces RAD51, RAD52 and RAD55 mutants.
    Valencia-Burton M; Oki M; Johnson J; Seier TA; Kamakaka R; Haber JE
    Genetics; 2006 Sep; 174(1):41-55. PubMed ID: 16782999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.